Bonus Episode: The Emerging Role of HRD Testing and the Progress of PARP Inhibitors in Ovarian Cancer

The EMJ Podcast: Insights For Healthcare Professionals

Jan 19 2023 • 41 mins

In this EMJ podcast episode, David O’Malley, Director of Gynecologic Oncology, Ohio State University, and the James Comprehensive Cancer Center, Columbus, Ohio, USA, and Christina Fotopoulou, Consultant Gynaecological Oncologist, Queen Charlotte’s & Chelsea Hospital, London, UK, discuss the role of homologous recombination deficiency (HRD) testing, and the progress of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer.

The publication of this podcast was funded by a medical educational grant from AstraZeneca with the purpose of enhancing the fundamental understanding of oncology specialists of the role and value of homologous recombination deficiency (HRD) testing and progress in the use of poly(ADP-ribose) polymerase (PARP) inhibitors.